{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:19:54Z","timestamp":1790824794161,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T00:00:00Z","timestamp":1764460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma GmbH","doi-asserted-by":"publisher","award":["UROA122024"],"award-info":[{"award-number":["UROA122024"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118849","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T07:53:58Z","timestamp":1764662038000},"page":"118849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Androgen receptor blockade and its effect on PSMA-localization in prostate cancer: Implications for radioligand therapy"],"prefix":"10.1016","volume":"193","author":[{"given":"Flavien","family":"Devaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareem","family":"Beltagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Frank","family":"Ermler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8051-329X","authenticated-orcid":false,"given":"Sven","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6566-5618","authenticated-orcid":false,"given":"Radu","family":"Alexa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Morgenroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Theodor Josef","family":"Vogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4579-3996","authenticated-orcid":false,"given":"Najaf","family":"Mammadbayli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6351-8056","authenticated-orcid":false,"given":"Matthias","family":"Saar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2025.118849_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.biopha.2025.118849_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00120-024-02505-1","article-title":"[Treatment algorithm following first-line therapy failure in metastatic prostate cancer]","volume":"64","author":"Thomas","year":"2025","journal-title":"Urologie"},{"issue":"3","key":"10.1016\/j.biopha.2025.118849_bib3","first-page":"543","article-title":"Practical implications of androgen receptor inhibitors for prostate cancer treatment. Explor Target Antitumor Ther","volume":"5","author":"Campodonico","year":"2024"},{"key":"10.1016\/j.biopha.2025.118849_bib4","doi-asserted-by":"crossref","first-page":"1134719","DOI":"10.3389\/fendo.2023.1134719","article-title":"Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: a systematic review and network meta-analysis","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118849_bib5","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1097\/RLU.0000000000002655","article-title":"Complete regression of lung metastases in a patient with metastatic castration-resistant prostate cancer using 177Lu-PSMA radioligand therapy","volume":"45","author":"Zhang","year":"2020","journal-title":"Clin. Nucl. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118849_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251375","article-title":"Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients","volume":"16","author":"Yadav","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2025.118849_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/RLU.0000000000002833","article-title":"Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"45","author":"Yadav","year":"2020","journal-title":"Clin. Nucl. Med."},{"issue":"35","key":"10.1016\/j.biopha.2025.118849_bib8","doi-asserted-by":"crossref","first-page":"25801","DOI":"10.1074\/jbc.M703268200","article-title":"Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone","volume":"282","author":"Askew","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"2 1","key":"10.1016\/j.biopha.2025.118849_bib9","first-page":"64","article-title":"Practical guide to the use of enzalutamide","volume":"21","author":"Hoffman-Censits","year":"2014","journal-title":"Can. J. Urol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118849_bib10","article-title":"Pharmacological Optimization of PSMA-Based Radioligand Therapy. Biomedicines","volume":"10","author":"van der Gaag","year":"2022"},{"issue":"7","key":"10.1016\/j.biopha.2025.118849_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071696","article-title":"Upregulation of PSMA expression by enzalutamide in patients with advanced mCRPC","volume":"14","author":"Rosar","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.biopha.2025.118849_bib12","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2967\/jnumed.117.191023","article-title":"177)Lu-PSMA radioligand therapy for prostate cancer","volume":"58","author":"Fendler","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"11","key":"10.1016\/j.biopha.2025.118849_bib13","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s00210-023-02539-w","article-title":"PSMA-617 inhibits proliferation and potentiates the (177)Lu-PSMA-617-induced death of human prostate cancer cells","volume":"396","author":"Zhao","year":"2023","journal-title":"Naunyn Schmiede Arch. Pharm."},{"issue":"18","key":"10.1016\/j.biopha.2025.118849_bib14","first-page":"4055","article-title":"Constitutive and antibody-induced internalization of prostate-specific membrane antigen","volume":"58","author":"Liu","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118849_bib15","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-025-07292-1","article-title":"PSMA PET\/CT in biochemical recurrence of prostate cancer with PSA levels <\/= 0.2 ng\/mL: a German multicenter analysis of conventional PSMA tracers, including [(68)Ga]Ga-PSMA-11, [(68)Ga]Ga-PSMA I&T, and [(18)F]PSMA-1007","author":"Burgard","year":"2025","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"issue":"3","key":"10.1016\/j.biopha.2025.118849_bib16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","article-title":"Overall survival and quality of life with [(177)Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118849_bib17","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233460","article-title":"Quantitative (68)Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following (177)Lu-PSMA-617 (VISION Trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"issue":"33","key":"10.1016\/j.biopha.2025.118849_bib18","doi-asserted-by":"crossref","first-page":"54051","DOI":"10.18632\/oncotarget.9912","article-title":"Prostate cancer and the unfolded protein response","volume":"7","author":"Storm","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.biopha.2025.118849_bib19","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.cell.2014.06.026","article-title":"stress-induced clearance of misfolded GPI-anchored proteins via the secretory pathway","volume":"158","author":"Satpute-Krishnan","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2025.118849_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103625","article-title":"Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase","volume":"72","author":"Lin","year":"2021","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.biopha.2025.118849_bib21","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.62347\/VJMW4904","article-title":"Synergistic combination therapy with ONC201 or ONC206, and enzalutamide or darolutamide in preclinical studies of castration-resistant prostate cancer","volume":"14","author":"Wu","year":"2024","journal-title":"Am. J. Cancer Res."},{"issue":"7","key":"10.1016\/j.biopha.2025.118849_bib22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrm2199","article-title":"Signal integration in the endoplasmic reticulum unfolded protein response","volume":"8","author":"Ron","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118849_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrm3270","article-title":"The unfolded protein response: controlling cell fate decisions under ER stress and beyond","volume":"13","author":"Hetz","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118849_bib24","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1101\/gad.12.7.982","article-title":"CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum","volume":"12","author":"Zinszner","year":"1998","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.biopha.2025.118849_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010020","article-title":"The response of prostate cancer to androgen deprivation and irradiation due to immune modulation","volume":"11","author":"Wu","year":"2018","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.biopha.2025.118849_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16112008","article-title":"Therapeutic and diagnostic potential of folic acid receptors and glycosylphosphatidylinositol (GPI) transamidase in prostate cancer","volume":"16","author":"Hoffmann","year":"2024","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.biopha.2025.118849_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2020.118765","article-title":"Src couples estrogen receptor to the anticipatory unfolded protein response and regulates cancer cell fate under stress","volume":"1867","author":"Yu","year":"2020","journal-title":"Biochim Biophys. Acta Mol. Cell Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118849_bib28","doi-asserted-by":"crossref","first-page":"R92","DOI":"10.1152\/ajpregu.00169.2010","article-title":"UPR induces transient burst of apoptosis in islets of early lactating rats through reduced AKT phosphorylation via ATF4\/CHOP stimulation of TRB3 expression","volume":"300","author":"Bromati","year":"2011","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.biopha.2025.118849_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ebiom.2016.04.018","article-title":"Glycosylation is an androgen-regulated process essential for prostate cancer cell viability","volume":"8","author":"Munkley","year":"2016","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.biopha.2025.118849_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41698-023-00363-2","article-title":"Rewiring of the N-Glycome with prostate cancer progression and therapy resistance","volume":"7","author":"Butler","year":"2023","journal-title":"NPJ Precis Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118849_bib31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/mc.23129","article-title":"Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer","volume":"59","author":"Peak","year":"2020","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.biopha.2025.118849_bib32","article-title":"Versatile functional energy metabolism platform working from research to patient: an integrated view of cell bioenergetics","volume":"3","author":"Loric","year":"2021","journal-title":"Front Toxicol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118849_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25116111","article-title":"Genomic characterization of preclinical prostate cancer cell line models","volume":"25","author":"Beatson","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.biopha.2025.118849_bib34","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1039\/D1CC05810J","article-title":"Prostate-specific membrane antigen (PSMA) targeted singlet oxygen delivery via endoperoxide tethered ligands","volume":"58","author":"Wang","year":"2022","journal-title":"Chem. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118849_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/genes13010135","article-title":"Expression of fibroblast activation protein is enriched in neuroendocrine prostate cancer and predicts worse survival","volume":"13","author":"Vlachostergios","year":"2022","journal-title":"Genes"},{"issue":"2","key":"10.1016\/j.biopha.2025.118849_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009852","article-title":"4-1BB agonist targeted to fibroblast activation protein alpha synergizes with radiotherapy to treat murine breast tumor models","volume":"13","author":"Garate-Soraluze","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.118849_bib37","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1021\/acs.molpharmaceut.2c01000","article-title":"Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging","volume":"20","author":"Wang","year":"2023","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.biopha.2025.118849_bib38","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.humpath.2007.03.014","article-title":"Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival","volume":"38","author":"Daneshmand","year":"2007","journal-title":"Hum. Pathol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118849_bib39","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.21873\/invivo.11640","article-title":"Predictive Value of Endoplasmic Reticulum Stress Markers in Low Ejection Fractional Heart Failure","volume":"33","author":"Sabirli","year":"2019","journal-title":"Vivo"},{"key":"10.1016\/j.biopha.2025.118849_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/814670","article-title":"Serum GRP78 as a Tumor Marker and Its Prognostic Significance in Non-Small Cell Lung Cancers: A Retrospective Study","volume":"2015","author":"Ma","year":"2015","journal-title":"Dis. Markers"},{"issue":"Pt 4","key":"10.1016\/j.biopha.2025.118849_bib41","article-title":"Increased N-glycosylation of PSMA by GnT-V enhances tumor malignancy through interacting with JAK2 and the subsequent STAT3-mediated transcriptional activation in prostate cancer","volume":"307","author":"Shi","year":"2025","journal-title":"Int J. Biol. Macromol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118849_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/ijch.202300162","article-title":"Protein Glycosylation Patterns Shaped By the IRE1-XBP1s Arm of the Unfolded Protein Response","volume":"64","author":"Chen","year":"2024","journal-title":"Isr. J. Chem."},{"issue":"21","key":"10.1016\/j.biopha.2025.118849_bib43","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1021\/acs.biochem.0c00969","article-title":"Integrated Structural Analysis of N-Glycans and Free Oligosaccharides Allows for a Quantitative Evaluation of ER Stress","volume":"60","author":"Fujitani","year":"2021","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.biopha.2025.118849_bib44","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s41467-020-15067-5","article-title":"Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy","volume":"11","author":"Mahameed","year":"2020","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biopha.2025.118849_bib45","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41568-023-00574-6","article-title":"Endocytosis in cancer and cancer therapy","volume":"23","author":"Banushi","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2025.118849_bib46","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10863-020-09846-4","article-title":"Lipid composition of the cancer cell membrane","volume":"52","author":"Szlasa","year":"2020","journal-title":"J. Bioenerg. Biomembr."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:04:27Z","timestamp":1777014267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225010431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":46,"alternative-id":["S0753332225010431"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118849","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Androgen receptor blockade and its effect on PSMA-localization in prostate cancer: Implications for radioligand therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118849"}}